Dier Biotech is proactively aligning with the Healthy China national strategy, ramping up R&D investment to drive industrial upgrading through innovation. At the event, Dier Bio’s staff showcased its clinical infectious disease diagnostics and monitoring product lines to distributors from both China and abroad, laboratory professionals, and representatives of medical institutions. The product portfolio includes: the DL‑SMS2 microbial rapid identification mass spectrometer, the DL‑96A fully automated bacterial identification and antimicrobial susceptibility testing system, the DL‑Bt series fully automated blood culture systems, the DL‑GBSB group A streptococcus culture and analysis system, as well as products for pathogen morphological detection and hospital infection management.

      MALDI-TOF MS, as a cutting-edge technology for clinical microbial identification, boasts high sensitivity, high accuracy, rapid sample analysis, and ease of operation. The DL‑SMS2 microbial rapid identification mass spectrometer is a rapid microbial identification system developed based on this technology, and it features… A proprietary standard mass spectral library and a rapid, accurate matching‑query algorithm drew numerous medical professionals, experts, and product distributors to visit and engage in discussions. The highly specialized on‑site demonstration positioned Dier Biotech as one of the most closely watched exhibits in the industry.

Through in‑person, in‑depth discussions and hands‑on demonstrations, Dier Biotech deepened customers’ understanding of the Dier brand and its products, while also securing prospective partners, thereby providing technical support to curb bacterial resistance and prevent the overuse of antibiotics.

Dier Biotechnology will keep pace with the times, deliver high-quality products and services, establish a leading national brand in microbial diagnostics, and work together to build a healthier China.